Alvotech and LOTTE Biologics have agreed a long term manufacturing partnership that will place production of drug substance for multiple antibody biosimilars at LOTTE’s Syracuse facility in New York.
The agreement expands Alvotech’s external production capacity in the United States while adding another biologics programme to the Syracuse operation. LOTTE will manufacture material for global supply, and the companies may extend the collaboration to further products as the initial programmes move through transfer and manufacturing.
Syracuse has 40,000 litres of installed bioreactor capacity alongside process development and quality control capabilities, allowing cell culture production, process support and analytical work to operate within the same manufacturing site. That infrastructure gives Alvotech access to an established regulated facility without waiting for a separate plant to be designed, constructed and qualified.
Antibody drug substance is produced biologically through engineered cells grown under controlled conditions inside bioreactors. As the cells multiply and metabolise nutrients they produce the required protein, which is subsequently separated and purified to remove cells, process residues and unwanted proteins before the material moves into later manufacturing stages.
Cell culture performance depends on temperature, nutrient concentration, dissolved gases, pH and other operating conditions remaining within defined ranges. Changes in those variables can alter yield and product characteristics, while increasing vessel scale changes mixing, oxygen transfer and heat removal rather than simply reproducing a smaller process at greater volume.
The 40,000 litres of installed capacity therefore describes the physical scale of the bioreactors rather than a fixed annual quantity of finished drug substance. Output depends on vessel configuration, duration of each production campaign, cell productivity, purification yield, cleaning and changeover time, and the quantity of material required for each biosimilar.
Biosimilar manufacturing adds tight product quality requirements because an antibody has to remain highly similar to its established reference medicine. Large biological molecules contain structural features influenced by the manufacturing process, so producers control critical quality attributes throughout cell culture, purification and analytical testing rather than relying on chemical identity alone.
Consistency consequently depends on the complete manufacturing chain from cell banks and media through bioreactor operation, purification and release testing. Each stage has to remain within validated limits across repeated batches, with LOTTE’s on site quality control capability providing analytical support while material moves through the Syracuse process.
Alvotech already operates large scale biosimilar manufacturing in Iceland, making Syracuse an additional production route rather than a replacement for its existing base. Geographic diversification can reduce dependence on one facility while also creating capacity for a portfolio that includes several antibody products moving through development and commercial supply.
US manufacturing can also shorten part of the physical supply chain for products serving the American market, although LOTTE will produce material for global use. Biological drug substance requires controlled handling, validated logistics and regulatory release, so the location of production influences the movement of intermediates and finished material between manufacturing stages.
LOTTE acquired the Syracuse site from Bristol Myers Squibb and has developed it as the basis of its US contract development and manufacturing operation. Existing bioreactors, utilities, analytical systems and regulated production infrastructure allow customer programmes to enter an operating site rather than depending on the construction schedule of a new facility.
Each Alvotech product will still require process transfer into the Syracuse equipment before routine commercial manufacturing begins. Operating parameters, raw materials, analytical methods and control strategies have to be reproduced on the receiving equipment and shown to deliver product quality consistent with the validated process.
Transfer work also has to account for differences in vessel geometry, control systems and supporting equipment between manufacturing locations. Mixing, gas transfer and process timing may require adjustment within validated ranges so the product remains comparable while the process is reproduced on a different production train.
Neither company has disclosed the financial value of the partnership, the individual biosimilars covered or the proportion of Syracuse capacity allocated to the programme. Those variables will determine how heavily the agreement loads the facility and how much capacity remains available for other products and customers.
Once transfer and qualification are complete, the manufacturing programme will be measured through repeated batch performance rather than nominal bioreactor volume. Stable cell culture, purification yield and analytical results will determine how effectively the installed capacity is converted into saleable biosimilar drug substance across the multiple antibody products covered by the agreement.
